A citation-based method for searching scientific literature

Sehhoon Park, Beung-Chul Ahn, Sung Won Lim, Jong-Mu Sun, Hye Ryun Kim, Min Hee Hong, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Yoon La Choi, Byoung Chul Cho, Myung-Ju Ahn. J Thorac Oncol 2018
Times Cited: 54



Justin F Gainor, Alice T Shaw. Oncologist 2013
Times Cited: 234




List of shared articles



Times cited

Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non-Small Cell Lung Carcinoma: the ROSING Study.
Esther Conde, Susana Hernandez, Rebeca Martinez, Barbara Angulo, Javier De Castro, Ana Collazo-Lorduy, Beatriz Jimenez, Alfonso Muriel, Jose Luis Mate, Teresa Moran,[...]. J Thorac Oncol 2019
37

Final Overall Survival, Safety, and Quality of Life Results From a Phase 2 Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced NSCLC.
Yi-Long Wu, Shun Lu, James Chih-Hsin Yang, Jianying Zhou, Takashi Seto, Myung-Ju Ahn, Wu-Chou Su, Noboru Yamamoto, Dong-Wan Kim, Jolanda Paolini,[...]. JTO Clin Res Rep 2022
0

Cases of ROS1-rearranged lung cancer: when to use crizotinib, entrectinib, lorlatinib, and beyond?
Kartik Sehgal, Andrew J Piper-Vallillo, Hollis Viray, Adeel M Khan, Deepa Rangachari, Daniel B Costa. Precis Cancer Med 2020
12

Treatment of oncogene-driven non-small cell lung cancer.
Elisabeth A Kastelijn, Adrianus J de Langen, Bas J M Peters. Curr Opin Pulm Med 2019
6

Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies.
Alberto D'Angelo, Navid Sobhani, Robert Chapman, Stefan Bagby, Carlotta Bortoletti, Mirko Traversini, Katia Ferrari, Luca Voltolini, Jacob Darlow, Giandomenico Roviello. Cancers (Basel) 2020
20

Effectiveness and prognostic factors of first-line crizotinib treatment in patients with ROS1-rearranged non-small cell lung cancer: A multicenter retrospective study.
Jing Zheng, He Cao, Yuping Li, Chuangzhou Rao, Te Zhang, Jiayou Luo, Dongqing Lv, Yanping Zhu, Jianya Zhou, Jianying Zhou. Lung Cancer 2020
5


Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial.
Alice T Shaw, Benjamin J Solomon, Rita Chiari, Gregory J Riely, Benjamin Besse, Ross A Soo, Steven Kao, Chia-Chi Lin, Todd M Bauer, Jill S Clancy,[...]. Lancet Oncol 2019
149

Uncommon targets in non-small cell lung cancer: Everyone wants a slice of cake.
Alessandro De Toma, Giuseppe Lo Russo, Diego Signorelli, Filippo Pagani, Giovanni Randon, Giulia Galli, Arsela Prelaj, Roberto Ferrara, Claudia Proto, Monica Ganzinelli,[...]. Crit Rev Oncol Hematol 2021
4

A Radiologist's Guide to the Changing Treatment Paradigm of Advanced Non-Small Cell Lung Cancer: The ASCO 2018 Molecular Testing Guidelines and Targeted Therapies.
Lydia Chen, Daniel A Smith, Bhanusupriya Somarouthu, Amit Gupta, Kianoush Ansari Gilani, Nikhil H Ramaiya. AJR Am J Roentgenol 2019
2

Different clinical features between patients with ROS1-positive and ALK-positive advanced non-small cell lung cancer.
Xianxiu Ji, Huikang Xie, Ren Zhu, Bin Chen, Sen Jiang, Jie Luo. J Int Med Res 2021
0